mRNA latecomer CureVac recruits Bayer to speed COVID-19 vaccine to market When will primary care docs get the COVID-19 vaccine? Many still in the dark Look out, pharma. A 'tidal wave' of side effect reports is coming amid COVID-19 vaccine rollouts AHA presses for changes to COVID-19 vaccine rollout and for HHS to take larger role Here's the latest CDC update clinicians should know when it comes to COVID-19 vaccine reactions Healthcare roundup: HHS extends community-based COVID-19 testing sites Biopharma roundup: Sanofi's Kevzara, Roche's Actemra curb death rates in U.K. trial In Los Angeles and beyond, oxygen is the latest COVID-19 bottleneck BioNTech CEO applies COVID-19 vaccine's mRNA tech to multiple sclerosis Featured Story | By Angus Liu Compared with Moderna and the Pfizer-BioNTech partnership, which already have their COVID-19 vaccines authorized for emergency use, CureVac seems a little late to the mRNA race. But now, Bayer has signed on to help accelerate development, boost manufacturing—and prep for a possible launch. read more |
| |
|---|
|
Top Stories By Heather Landi While front-line hospital workers across the country began receiving the COVID-19 vaccine last month, many primary care doctors have no direct link to the vaccine rollout and are left in the dark about their turn in line. read more By Eric Sagonowsky With COVID-19 vaccine launches gaining steam—and an unprecedented level of media coverage zeroed in—pharma companies of all stripes should brace for a wave of side effect reports, experts say. And it won't just intensify adverse-event tracking, but the threat of lawsuits, too. read more By Robert King AHA gave HHS some recommendations to improve the rollout of the COVID-19 vaccine after some hospitals have complained of disparate plans between states. read more By Tina Reed Docs are fielding plenty of questions about the COVID-19 vaccine right now. Here's a look at the latest data from the Centers for Disease Control and Prevention. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner Big Pharma Bayer is helping CureVac on its mRNA vaccine. Arthritis drugs from Roche and Sanofi helped the sickest patients in a U.K.-funded COVID-19 trial. Aspen could start producing J&J doses in March or April. Peru inked vaccine orders with Sinopharm and AstraZeneca. Plus, Sinovac's shot proved 78% effective in phase 3. read more By Lauren Weber,Rae Ellen Bichell, Kaiser Health News As Los Angeles hospitals give record numbers of covid patients oxygen, the systems and equipment needed to deliver the life-sustaining gas are faltering. read more By Angus Liu The new vaccine technology mRNA is making waves these days as COVID-19 shots based on it deliver efficacy that’s unrivaled by other platforms. BioNTech's Pfizer-partnered vaccine Comirnaty is one of those vaccines. Now, the German biotech’s CEO, Ugur Sahin, has led a study showing an mRNA vaccine was effective against multiple sclerosis in mice. read more |
